

CureVac's mRNA based Vaccine Candidate against SARS-CoV-2

Data update [redacted]

Pre-read for [redacted] EU Member state experts review

- STRICTLY CONFIDENTIAL -

Key elements (1/2)

1 CureVac's mRNA platform

- Pioneer in developing mRNA vaccines and therapies; broad IP position: [redacted]
- CureVac's [redacted]
- External validation of platform: Strategic partnerships with [redacted]

2 CVnCoV construct and preclinical data

- Clinical COVID-19 vaccine candidate selected based on biological properties (preclinical immunogenicity and safety) characterized in vitro and in vivo (mice and rats) and large scale manufacturability
- [redacted]

3 Available CVnCoV Ph1 clinical data

- [redacted]

Key elements (2/2)

4 Clinical development plan and project timelines

-
-
-
-
-

5 Manufacturing footprint, capacity and delivery plan

-
-
-

6 Target presentation and shelf-life

-
-
-
-

1. CureVac's mRNA Platform

Creates Unique, IP-protected Product Candidates

1 Identification of a target expression profile for each mRNA product candidate

2 [redacted] provides optimal mRNA solutions for each target indication

3 The optimization process allows us to pursue new and exclusive IP protection for each product candidate across our focus areas and proprietary technologies



Protein Design: Enables the Optimization of Specific Properties of the Encoded Protein





2. CVnCoV Construct and Pre-Clinical Data

Fast-Track SARS-CoV-2 Vaccine Development

Development Plan overview and timeline

CVnCoV Induces [redacted]

CVnCoV Induces a [redacted]



Characterization of humoral and cellular responses:

Values in log(x)

3. Available CVnCoV Clinical Data

Overview of Clinical Study Design of [redacted]

Ongoing Phase 1 Results Indicate

Systemic and Local Solicited Events by Dose Level and Dosing Occasion
(as % of subjects at each time point)

4. Clinical Development Plan and Project Timelines

- Study:
- Study goal:



CureVac will

Key Project Milestones in [redacted]

#	Milestone	Planned Date
1	[redacted]	
2		
3		
4		
5		
6		
7		
8		

5. Manufacturing Footprint, Capacity Increase and Delivery Plan for EU APA

CureVac is

Strictly confidential –





6. Vaccine Presentation and Shelf-Life

CVnCoV Presentations Upon Approval

[redacted]

[redacted]

Target stability

- [redacted]
- [redacted]

Ongoing data collection to support target stability profile

- [redacted]
- [redacted]

Perspective on feasibility of achieving target profile

- [redacted]
- [redacted]
- [redacted]

Stability Data for



CureVac AG
Friedrich-Miescher-Strasse 15
72076 Tübingen, Germany
T +49 7071 9883-0
www.curevac.com

RNActive® RNArt® RNAdjuvant® PureMessenger® RNAntigen® RNAntibody® RNAnimal® CVCM® The RNA Printer®